Image
PCP of innovative ICT for patient empowerment and self-management for patients with diabetes
Published on 25 April 2020
Portugal
This is the good practice's implementation level. It can be national, regional or local.
About this good practice
Worldwide healthcare systems are facing an increase of diabetes in the population, hence in the costs associated with the disease. The market was just offering partial solution, consequently, the disease is expected to grow globally from 8.8% in 2015 to 10.4% in 2040 if no effective counter measures are put in place.
The project assumes that the quality of medical decisions can be enhanced by personalised support tools that summarise patient clinical characteristics, treatment preference and ancillary data at the point of care.
To find suppliers to develop these tools, ProEmpower uses PCP as their main IPP instrument. Their PCP is divided in 5 steps: 3 phases and 2 pre-phases. The 2 pre-phases are Open Market Consultation and Calls for Tenders. The 3 following phases are Solution Design, Prototype Development and finally Development of Pilot System and Testing.
The main stakeholders are:
1. Serviços Partilhados do Ministério da Saúde, EPE (Portugal)
2. Türkiye Cumhuriyeti Sağlık Bakanlığı (Turkey)
3. Servicio Murciano de Salud (Spain)
4. Soggetto Aggregatore della Regione Campania (Italy)
Besides, the stakeholders count with the support of a team of researchers, consultants and national health care institutions such as Santa Casa da Misericórdia da Amadora (SCMA). The beneficiaries of the practice are: Patients with diabetes II mellitus, patient’s families, healthcare systems and the society in general.
The project assumes that the quality of medical decisions can be enhanced by personalised support tools that summarise patient clinical characteristics, treatment preference and ancillary data at the point of care.
To find suppliers to develop these tools, ProEmpower uses PCP as their main IPP instrument. Their PCP is divided in 5 steps: 3 phases and 2 pre-phases. The 2 pre-phases are Open Market Consultation and Calls for Tenders. The 3 following phases are Solution Design, Prototype Development and finally Development of Pilot System and Testing.
The main stakeholders are:
1. Serviços Partilhados do Ministério da Saúde, EPE (Portugal)
2. Türkiye Cumhuriyeti Sağlık Bakanlığı (Turkey)
3. Servicio Murciano de Salud (Spain)
4. Soggetto Aggregatore della Regione Campania (Italy)
Besides, the stakeholders count with the support of a team of researchers, consultants and national health care institutions such as Santa Casa da Misericórdia da Amadora (SCMA). The beneficiaries of the practice are: Patients with diabetes II mellitus, patient’s families, healthcare systems and the society in general.
Resources needed
Overall, the EU contribution to the project was 3 852 677,27€. From the industry budget, PCP phases required 450 000€ to Phase 1; 900 000€ to Phase 2 and 1 650 000€ to Phase 3. The EU contribution to the Portuguese stakeholders was respectively 735 384,38€ to SPMS and 70 003,13€ to SCMA.
Evidence of success
ProEmpower will serve 12 million diabetes patients. From the demand side, the advantages are in the reductions of diabetes-related death, amputation, blindness and renal failure promise total cost relief of 53 billion € over 7 years in the four countries.
From the supply side, suppliers can expect a turnover of 5 billion € a year. ProEmpower suppliers are expected to entry onto other EU or overseas markets, a strong contribution to fragmentation of demand and fostering the global market.
From the supply side, suppliers can expect a turnover of 5 billion € a year. ProEmpower suppliers are expected to entry onto other EU or overseas markets, a strong contribution to fragmentation of demand and fostering the global market.
Potential for learning or transfer
ProEmpower provides potential for learning or transfer from different perspectives.
From a general perspective, if the main institution in charge (SPMS) performs successful models of recognized IPP practices, such as Open Market Consultation and PCP, these practices could be reproduced and transferred to other opportunities by other buyers. For example, the SPMS Pre-Commercial Procurement model could serve as an inspiration to other purchase centers and public entities performing IPP.
From a sectorial perspective, the SPMS experience generates learning for the Health Sector. If their practices succeed, they can change the mindset of other public healthcare entities and stimulate them to finance or buy Innovation and that would consequently encourage IPP in the Health Sector in Portugal.
From a general perspective, if the main institution in charge (SPMS) performs successful models of recognized IPP practices, such as Open Market Consultation and PCP, these practices could be reproduced and transferred to other opportunities by other buyers. For example, the SPMS Pre-Commercial Procurement model could serve as an inspiration to other purchase centers and public entities performing IPP.
From a sectorial perspective, the SPMS experience generates learning for the Health Sector. If their practices succeed, they can change the mindset of other public healthcare entities and stimulate them to finance or buy Innovation and that would consequently encourage IPP in the Health Sector in Portugal.
Further information
Website
Good practice owner
You can contact the good practice owner below for more detailed information.
Organisation
Serviços Partilhados Ministério da Saúde - SPMS
Portugal
Área Metropolitana de Lisboa
Contact